Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells

Cancer Research

Volumn 64, Issue 1, 2004, Pages 386-390

  Chamoto, Kenji ^a   Tsuji, Takemasa ^a   Funamoto, Hiromi ^a   Kosaka, Akemi ^a   Matsuzaki, Junko ^a   Sato, Takeshi ^a   Abe, Hiroyuki ^a   Fujio, Keishi ^b   Yamamoto, Kazuhiko ^b   Kitamura, Toshio ^c   Takeshima, Tsuguhide ^a   Togashi, Yuji ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; OVALBUMIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS;

EID: 9144239842     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2596     Document Type: Article

References (30)

1. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol., 3: 133-146, 2003.
2. Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ota, A., Koda, T., and Nishimura, S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol., 46: S52-S61, 2000.
3. Tada, T., Ohzeki, S., Utsumi, K., Takiuchi, H., Muramatsu, M., Li, X. F., Shimizu, J., Fujiwara, H., and Hamaoka, T. Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol., 146: 1077-1082, 1991.
4. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev., 182: 18-32, 2001.
5. Kobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., Ramanathapuram, L. V., Arteaga, C. L., and Akporiaye, E. T. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res., 63: 1860-1864, 2003.
6. Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., and Ohta, A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med., 190: 617-627, 1999.
7. Fujio, K., Misaki, Y., Setoguchi, K., Morita, S., Kawahata, K., Kato, I., Nosaka, T., Yamamoto, K., and Kitamura, T. Functional reconstitution of class 11 MHC-restricted T cell immunity mediated by retroviral transfer of the αβ TCR complex. J. Immunol., 165: 528-532, 2000.
8. Kessels, H. W., Wolkers, M. C., Van den Boom, M. D., Van der Valk, M. A., and Schumacher, T. N. Immunotherapy through TCR gene transfer. Nat. Immunol., 2: 957-961, 2001.
9. Stanislawski, T., Voss, R. H., Lotz, C., Sadovnikova, E., Willemsen, R. A., Kuball, J., Ruppert, T., Bolhuis, R. L., Melief, C. J., Huber, C., Stauss, H. J., and Theobald, M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol., 2: 962-970, 2001.
10. Tsuji, T., Chamoto, K., Funamoto, H., Kosaka, A., Matsuzaki, J., Abe, H., Fujio, K., Yamamoto, K., Kitamura, T., Togashi, Y., Koda, T., and Nishimura, T. An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapy. Cancer Sci., 94: 389-393, 2003.
11. Nishimura, T., Burakoff, S. J., and Herrmann, S. H. Protein kinase C required for cytotoxic T lymphocyte triggering. J. Immunol., 139: 2888-2891, 1987.
12. Ohta, S., Tsukamoto, H., Watanabe, K., Makino, K., Kuge, S. Hanai, N., Habu, S., and Nishimura, T. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol. Lett., 44: 35-40, 1995.
13. Indraccolo, S., Habeler, W., Tisato, V., Stievano, L., Piovan, E., Tosello, V., Esposito, G., Wagner, R., Uberla, K., Chieco-Bianchi, L., and Amadori, A. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res., 62: 6099-6107, 2002.
14. Bennett, S. R., Carbone, R. F., Karamalis, F., Flavell, R. A., Miller, J. F., and Heath, W. R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (Lond.), 393: 478-480, 1998.
15. Schoenberger, S. P., Toes, R. E., Van der Voort, E. I., Offringa, R., and Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393: 480-483, 1998.
16. + T-helper and a T-killer cell. Nature (Lond.), 393: 474-478, 1998.
17. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol., 165: 6047-6055, 2000.
18. + T cells. J. Exp. Med., 197: 985-995, 2003.
19. Sato, M., Chamoto, K., and Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int. Immunol., 15: 837-843, 2003.
20. + T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood, 89: 2529-2536, 1997.
21. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E., and Celis, E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res., 61: 4773-4778, 2001.
22. + T cells. Cancer Res., 62: 213-218, 2002.
23. Kobayashi, H., Omiya, R., Ruiz, M., Huarte, E., Sarobe, P., Lasarte, J. J., Herraiz, J., Sangro, B., Prieto, J., Borras-Cuesta, F., and Celis, E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin. Cancer Res., 8: 3219-3225, 2002.
24. Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., and Storkus, W. J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med., 196: 619-628, 2002.
25. Giuntoli, R. L., II, Lu, J., Kobayashi, H., Kennedy, R., and Celis, E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin. Cancer Res., 8: 922-931, 2002.
26. Nakajima, C., Uekusa, Y., Iwasaki, M., Yamaguchi, N., Mukai, T., Gao, P., Tomura, M., Ono, S., Tsujimura, T., Fujiwara, H., and Hamaoka, T. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice. Cancer Res., 61: 3399-3405, 2001.
27. Uekusa, Y., Gao, P., Yamaguchi, N., Tomura, M., Mukai, T., Nakajima, C., Iwasaki, M., Takeuchi, N., Tsujimura, T., Nakazawa, M., Fujiwara, H., and Hamaoka, T. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J. Leukoc. Biol., 72: 864-873, 2002.
28. Plautz, G. E., Inoue, M., and Shu, S. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors., Cell. Immunol., 171: 277-284, 1996.
29. Ganss, R., Ryschich, E., Klar, E., Arnold, B., and Hammerling, G. J. Combination of T-cell therapy and trigger of inflammation induce remodeling of the vasculature and tumor eradication. Cancer Res., 62: 1462-1470, 2002.
30. Mesnil, M., and Yamasaki, H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res., 60: 3989-3999, 2000.